Global Information
회사소개 | 문의 | 비교리스트

전립선 비대증 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2019-2027년)

Benign Prostatic Hyperplasia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

리서치사 Transparency Market Research
발행일 2019년 08월 상품 코드 910592
페이지 정보 영문 220 Pages
가격
US $ 5,795 ₩ 6,977,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 인쇄는 가능하지만, 전체 페이지 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,795 ₩ 10,589,000 PDF by E-mail (5-user License) help
5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 전체 페이지 인쇄는 1명당 1회로 한정하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,795 ₩ 14,201,000 PDF by E-mail (Corporate License) help
기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


전립선 비대증 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2019-2027년) Benign Prostatic Hyperplasia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
발행일 : 2019년 08월 페이지 정보 : 영문 220 Pages

세계의 전립선 비대증 치료(Benign Prostatic Hyperplasia)에 대해 조사했으며, 시장 기회와 동향, 성장 촉진요인 및 저해요인, 치료·최종사용자·지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 서론

  • 보고서의 범위 및 시장 세분화
  • 조사 하이라이트

제2장 전제조건 및 조사 방법

  • 전제조건 및 사용된 약어
  • 조사 방법

제3장 주요 요약

  • 시장 규모 및 분포 : 지역별
  • 시장 현황

제4장 시장 개요

  • 치료 개요
  • 주요 산업의 발전
  • 시장 역학
  • 성장 촉진요인 및 저해요인 현황 분석
  • 성장 촉진요인
  • 성장 저해요인
  • 시장 기회
  • 시장 매출 예측

제5장 프리미엄 인사이트

  • 임상시험 파이프라인 분석
  • 미국의 유병률
  • 상환 시나리오
  • 주요 인수합병
  • 수술 건수
  • 기업별 시장 점유율 분석
  • 치료 평균 비용
  • 제품/브랜드 분석
    • Urolift
    • Rezum

제6장 시장 분석 : 치료별

  • 서론
  • 시장 규모 및 예측
    • 약물 클래스
    • 최소침습 수술
    • 레이저 치료
    • 기타
  • 시장 분석
  • 시장의 매력 분석

제7장 시장 분석 : 최종사용자별

  • 서론
  • 시장 규모 및 예측
    • 병원
    • 외래수술센터
    • 전문 클리닉
    • 기타
  • 시장 분석
  • 시장의 매력 분석

제8장 시장 분석 : 지역별

  • 시장 규모 및 예측
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장 분석
  • 시장의 매력 분석

제9장 북미

제10장 유럽

제11장 아시아태평양

제12장 라틴아메리카

제13장 중동 및 아프리카

제14장 경쟁 구도(제약기업)

  • 기업 개요
    • Abbott
    • Allergan plc
    • Astellas Pharma, Inc.
    • Asahi Kasei Corporation
    • Boehringer Ingelheim GmbH
    • GlaxoSmithKline plc
    • Pfizer, Inc.
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.

제15장 경쟁 구도(의료기기/서비스 프로바이더)

  • 기업 개요
    • Boston Scientific Corporation
    • Teleflex Incorporated
    • Endo International plc
    • Urologix, LLC
    • LISA Laser
    • Olympus Corpor
LSH 19.09.26

List of Tables

  • TABLE 1 Prostate Cancer Therapeutics : Pipeline Analysis - Phase III (1/2)
  • TABLE 2 Prostate Cancer Therapeutics : Pipeline Analysis - Phase III (2/2)
  • TABLE 3 Prostate Cancer Therapeutics : Pipeline Analysis - Phase II (1/2)
  • TABLE 4 Prostate Cancer Therapeutics : Pipeline Analysis - Phase II (2/2)
  • TABLE 5 Prostate Cancer Therapeutics : Pipeline Analysis - Phase I
  • TABLE 6 2015 Patient Population Break Down
  • TABLE 7 Number of Surgeries (Unit Procedures) Performed in United States (2018)
  • TABLE 8 Summary of Current BPH Treatments in U.S.
  • TABLE 9 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 10 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 11 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2027
  • TABLE 12 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 13 Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2016-2026
  • TABLE 14 North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country, 2016-2026
  • TABLE 15 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 16 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 17 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2027
  • TABLE 18 North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • TABLE 19 Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 20 Europe Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 21 Europe Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 22 Europe Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2027
  • TABLE 23 Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 24 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 25 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 26 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 27 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2027
  • TABLE 28 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 29 Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 30 Latin America Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 31 Latin America Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 32 Latin America Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2027
  • TABLE 33 Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027
  • TABLE 34 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • TABLE 35 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2027
  • TABLE 36 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2027
  • TABLE 37 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2027
  • TABLE 38 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2027

List of Figures

  • FIG. 1 Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, 2017-2027
  • FIG. 2 Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Treatment, 2018
  • FIG. 3 Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Drug Class, 2018
  • FIG. 4 Global Benign Prostatic Hyperplasia Treatment Market Value Share, by End-user, 2018
  • FIG. 5 Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Minimally Invasive Surgery, 2018
  • FIG. 6 Global Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • FIG. 7 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Drug Class, 2017-2027
  • FIG. 8 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Minimally Invasive Surgeries, 2017-2027
  • FIG. 9 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Laser Therapy, 2017-2027
  • FIG. 10 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Others, 2017-2027
  • FIG. 11 Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2019-2027
  • FIG. 12 Global Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • FIG. 13 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Hospitals, 2017-2027
  • FIG. 14 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Ambulatory Surgical Centers, 2017-2027
  • FIG. 15 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Specialty Clinics, 2017-2027
  • FIG. 16 Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Others, 2017-2027
  • FIG. 17 Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2019-2027
  • FIG. 18 Global Benign Prostatic Hyperplasia Treatment Market Value Share (%), by Region, 2018 and 2026
  • FIG. 19 Global Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Region, 2018-2026
  • FIG. 20 North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • FIG. 21 North America Benign Prostatic Hyperplasia Treatment Market Value Share, by Country, 2017 and 2026
  • FIG. 22 North America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country, 2018-2026
  • FIG. 23 North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2017 and 2026
  • FIG. 24 North America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2018-2026
  • FIG. 25 North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2017 and 2026
  • FIG. 26 North America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2018-2026
  • FIG. 27 Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019-2027
  • FIG. 28 Europe Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • FIG. 29 Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • FIG. 30 Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • FIG. 31 Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019-2027
  • FIG. 32 Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • FIG. 33 Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019-2027
  • FIG. 34 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019-2027
  • FIG. 35 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • FIG. 36 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • FIG. 37 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • FIG. 38 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019-2027
  • FIG. 39 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • FIG. 40 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019-2027
  • FIG. 41 Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019-2027
  • FIG. 42 Latin America Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • FIG. 43 Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • FIG. 44 Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • FIG. 45 Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019-2027
  • FIG. 46 Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • FIG. 47 Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019-2027
  • FIG. 48 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019-2027
  • FIG. 49 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • FIG. 50 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • FIG. 51 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • FIG. 52 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019-2027
  • FIG. 53 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • FIG. 54 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019-2027
  • FIG. 55 Global Benign Prostatic Hyperplasia Treatment Devices Market Share Analysis, by Company, 2018
  • FIG. 56 GlaxoSmithKline plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 57 GlaxoSmithKline plc. R&D Expenses and Selling, General and Administration Expenses (US$ Bn) - Company Level, 2015-2018
  • FIG. 58 GlaxoSmithKline plc. Breakdown of Net Sales, by Region/Country (Company Level), 2018
  • FIG. 59 GlaxoSmithKline plc. Breakdown of Net Sales, by Business Segment (Overall Company Level), 2018
  • FIG. 60 Sanofi R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • FIG. 61 Sanofi Breakdown of Net Sales (%), by Region/Country, 2018
  • FIG. 62 Sanofi Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 63 Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2018
  • FIG. 64 Pfizer, Inc. Breakdown of Net Sales, by Region/Country, 2018
  • FIG. 65 Pfizer, Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2015-2018
  • FIG. 66 Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2018
  • FIG. 67 Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • FIG. 68 Teva Pharmaceutical Industries Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • FIG. 69 Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2018
  • FIG. 70 Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Operating Segment, 2017
  • FIG. 71 Abbott Laboratories Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2018
  • FIG. 72 Abbott Laboratories R&D Intensity and Sales & Marketing Intensity - Company Level, 2016-2018
  • FIG. 73 Abbott Laboratories Breakdown of Net Sales, by Segment, 2018
  • FIG. 74 Abbott Breakdown of Net Sales (%), by Country/Sub-region, 2018
  • FIG. 75 Allergan plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • FIG. 76 Allergan plc Breakdown of Net Sales (%), by Geography, 2018
  • FIG. 77 Allergan plc R&D Expenses and Marketing & Sales Intensity (%) 2016-2018
  • FIG. 78 Allergan plc Breakdown of Net Sales (%), by Business Segment, 2018
  • FIG. 79 Endo Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 80 Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Region, 2016
  • FIG. 81 Endo Pharmaceuticals, Inc. total Acquisition-related and Integration Items, Expenses in 2016-2018
  • FIG. 82 Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Specialty Products, 2018
  • FIG. 83 Boehringer Ingelheim GmbH Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 84 Boehringer Ingelheim GmbH Breakdown of Net Sales, by Region (Company Level), 2018
  • FIG. 85 Boehringer Ingelheim GmbH Breakdown of Net Sales, by Business and Business Segment Level, 2017
  • FIG. 86 Boehringer Ingelheim GmbH R&D Expenditure (US$ Mn), 2016-2018
  • FIG. 87 Merck & Co., Inc. Break-up of Net Sales, by Region, 2017
  • FIG. 88 Merck & Co., Inc. Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • FIG. 89 Merck & Co., Inc. R&D Intensity (%) - Company Level or Segment Level, 2014-2017
  • FIG. 90 Asahi Kasei Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • FIG. 91 Asahi Kasei Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • FIG. 92 Asahi Kasei Corporation Breakdown of Net Sales (%), by Business Segment, 2018
  • FIG. 93 Astellas Pharma, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 94 Astellas Pharma, Inc. Breakdown of Net Sales (%), by Region, 2016
  • FIG. 95 Astellas Pharma, Inc. R&D expenses (US$ Bn) in 2016-2018
  • FIG. 96 Astellas Pharma, Inc. Breakdown of Net Sales (%), by Main Products, 2018
  • FIG. 97 Teleflex Incorporated, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • FIG. 98 Teleflex Incorporated, Breakdown of Net Sales (%), by Business Segment, 2018
  • FIG. 99 Teleflex Incorporated, Breakdown of Net Sales (%), by Geography, 2018
  • FIG. 100 Boston Scientific Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
  • FIG. 101 Boston Scientific Corporation Breakdown of Net Sales (%), by Business Segment, 2018
  • FIG. 102 Boston Scientific Corporation Breakdown of Net Sales (%), by Country, 2017
  • FIG. 103 Boston Scientific Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • FIG. 104 Olympus Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2018
  • FIG. 105 Olympus Corporation Breakdown of Net Sales (%), by Region, 2018
  • FIG. 106 Olympus Corporation Breakdown of Net Sales (%), by Medical Business Segment, 2018

Title:
Benign Prostatic Hyperplasia Treatment Market (Treatment: Drug Class, Minimally Invasive Surgeries, Laser Therapy, and Others; End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027.

Scope of the Report

Transparency Market Research (TMR), in its recently published research report, quantifies the growth of the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027. This exclusive research report on the global benign prostatic hyperplasia treatment market offers a detailed overview of the benign prostatic hyperplasia treatment market, uncovering significant aspects and segmentations based on numerous parameters. This comprehensive research report also talks about the research methodologies being adopted in order to estimate precise market numbers. This detailed business guide also includes relevant charts and tables, in order to enable stakeholders get an incisive outlook of the benign prostatic hyperplasia treatment market for the forecast period.

This statistical business report analyzes, at length, crucial insights obtained by this exclusive study. With the aid of rare and distinguished insights enumerated in this comprehensive research report, stakeholders in the benign prostatic hyperplasia treatment market can form business growth strategies to gain an upper hand over their competitors. Various factors accounted for the benign prostatic hyperplasia treatment market's upward growth trajectory are discussed at length in this research report. Additionally, the research report identifies and explains the key drivers, threats, restraints, and opportunities present in the benign prostatic hyperplasia treatment market.

This broad study of the global benign prostatic hyperplasia treatment market assesses the growth drivers and restraints at length. This exhaustive study of important factors can aid market players in understanding the challenges present in the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027. The detailed research report gauges the bargaining power of buyers and suppliers, threats arising from new market entrants and substitutes, and the degree of competition present in the benign prostatic hyperplasia treatment market. Influence exerted on the benign prostatic hyperplasia treatment market by the government policies is also discussed in this research report.

Segmentation

This comprehensive research report encompasses the technological advancements and recent trends to gain a better perspective of the growth of the benign prostatic hyperplasia treatment market. In order to aid market players in having a precise market approach, our analysts have bifurcated the benign prostatic hyperplasia treatment market into key segments - treatment, end user, and region. Key segments of the benign prostatic hyperplasia treatment market are as mentioned below:

Key Questions Answered:

This comprehensive research report analyzes and answers crucial questions related to the growth of the benign prostatic hyperplasia treatment market during the forecast period.

Some of the key questions answered in this study are as follows:

  • What are the key developments and important market shifts expected to be observed in the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027?
  • What are the key strategies followed by market participants functioning in the benign prostatic hyperplasia treatment market?
  • What are some of the important recent developments that the new market participants should look at?
  • Which treatment will be the top-selling one in the benign prostatic hyperplasia treatment market?

Research Methodology

The research approach taken by analysts at Transparency Market Research (TMR) includes a robust methodology for obtaining key insights into the benign prostatic hyperplasia treatment market for the forecast period of 2019-2027. Interviews were conducted with important market participants, opinion leaders, vendors, distributors, and industry experts. In addition to this, a detailed secondary study of company websites, industry associations, marketing collaterals, and government statistics is carried out.

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Assumptions and Acronyms Used
  • 2.2. Research Methodology

3. Executive Summary

  • 3.1. Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
  • 3.2. Global Benign Prostatic Hyperplasia Treatment Market: Market Snapshot

4. Market Overview

  • 4.1. Global Benign Prostatic Hyperplasia Treatment Market: Treatment Overview
  • 4.2. Global Benign Prostatic Hyperplasia Treatment Market: Key Industry Developments
  • 4.3. Market Dynamics
  • 4.4. Drivers and Restraints Snapshot Analysis
  • 4.5. Drivers
    • 4.5.1. Increasing Aging Men Population All Over the World
    • 4.5.2. Expanding Patient Pool Due to Other Risk Factors
  • 4.6. Restraints
    • 4.6.1. Insufficient Healthcare Facilities and Unawareness of BPH Condition
    • 4.6.2. Patent Expiration of Benign Prostatic Hyperplasia Drugs
  • 4.7. Opportunities
  • 4.8. Global Benign Prostatic Hyperplasia Treatment Market Revenue Projections (US$ Mn), 2017-2027

5. Key Insights

  • 5.1. Clinical Trial Pipeline Analysis
  • 5.2. U.S. Prevalence of Benign Prostatic Hyperplasia
  • 5.3. Re-imbursement Scenario
  • 5.4. Key Merger and Acquisitions
  • 5.5. Number of Surgeries (Unit Procedures) Performed, 2018
  • 5.6. Competitive Market Share Analysis, by Company, 2018
  • 5.7. Average Cost of Benign Prostatic Hyperplasia Treatment
  • 5.8. Product/Brand Analysis - 2018
    • 5.8.1. Urolift
    • 5.8.2. Rezum

6. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment

  • 6.1. Introduction
  • 6.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
    • 6.2.1. Drug Class
      • 6.2.1.1. Alpha-blockers
      • 6.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
      • 6.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 6.2.1.4. Others
    • 6.2.2. Minimally Invasive Surgeries
      • 6.2.2.1. Transurethral Resection of the Prostate (TURP)
      • 6.2.2.2. Transurethral Incision of the Prostate (TUIP)
      • 6.2.2.3. Robotic Surgeries
      • 6.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
      • 6.2.2.5. Prostatic Urethral Lift
      • 6.2.2.6. Others
    • 6.2.3. Laser Therapy
    • 6.2.4. Others
  • 6.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment
  • 6.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment

7. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user

  • 7.1. Introduction
  • 7.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
    • 7.2.1. Hospitals
    • 7.2.2. Ambulatory Surgical Centers
    • 7.2.3. Specialty Clinics
    • 7.2.4. Others
  • 7.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user
  • 7.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user

8. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region

  • 8.1. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Region, 2017-2027
    • 8.1.1. North America
    • 8.1.2. Europe
    • 8.1.3. Asia Pacific
    • 8.1.4. Latin America
    • 8.1.5. Middle East & Africa
  • 8.2. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region
  • 8.3. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Region

9. North America Benign Prostatic Hyperplasia Treatment Market Analysis

  • 9.1. North America Benign Prostatic Hyperplasia Treatment Market
  • 9.2. North America Benign Prostatic Hyperplasia Treatment Market Overview
  • 9.3. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
    • 9.3.1. Drug Class
      • 9.3.1.1. Alpha-blockers
      • 9.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
      • 9.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 9.3.1.4. Others
    • 9.3.2. Minimally Invasive Surgeries
      • 9.3.2.1. Transurethral Resection of the Prostate (TURP)
      • 9.3.2.2. Transurethral Incision of the Prostate (TUIP)
      • 9.3.2.3. Robotic Surgeries
      • 9.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
      • 9.3.2.5. Prostatic Urethral Lift
      • 9.3.2.6. Others
    • 9.3.3. Laser Therapy
    • 9.3.4. Others
  • 9.3.5.
  • 9.4. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
    • 9.4.1. Hospitals
    • 9.4.2. Ambulatory Surgical Centers
    • 9.4.3. Specialty Clinics
    • 9.4.4. Others
  • 9.5. North America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
    • 9.6.1. By Treatment
    • 9.6.2. By End-user
    • 9.6.3. By Country

10. Europe Benign Prostatic Hyperplasia Treatment Market Analysis

  • 10.1. Europe Benign Prostatic Hyperplasia Treatment Market
  • 10.2. Europe Benign Prostatic Hyperplasia Treatment Market Overview
  • 10.3. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
    • 10.3.1. Drug Class
      • 10.3.1.1. Alpha-blockers
      • 10.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
      • 10.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 10.3.1.4. Others
    • 10.3.2. Minimally Invasive Surgeries
      • 10.3.2.1. Transurethral Resection of the Prostate (TURP)
      • 10.3.2.2. Transurethral Incision of the Prostate (TUIP)
      • 10.3.2.3. Robotic Surgeries
      • 10.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
      • 10.3.2.5. Prostatic Urethral Lift
      • 10.3.2.6. Others
    • 10.3.3. Laser Therapy
    • 10.3.4. Others
  • 10.4. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
    • 10.4.1. Hospitals
    • 10.4.2. Ambulatory Surgical Centers
    • 10.4.3. Specialty Clinics
    • 10.4.4. Others
  • 10.5. Europe Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
    • 10.5.1. U.K.
    • 10.5.2. France
    • 10.5.3. Germany
    • 10.5.4. Spain
    • 10.5.5. Italy
    • 10.5.6. Rest of Europe
  • 10.6. Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
    • 10.6.1. By Treatment
    • 10.6.2. By End-user
    • 10.6.3. By Country/Sub-region

11. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis

  • 11.1. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Key Findings
  • 11.2. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Overview
  • 11.3. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
    • 11.3.1. Drug Class
      • 11.3.1.1. Alpha-blockers
      • 11.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
      • 11.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 11.3.1.4. Others
    • 11.3.2. Minimally Invasive Surgeries
      • 11.3.2.1. Transurethral Resection of the Prostate (TURP)
      • 11.3.2.2. Transurethral Incision of the Prostate (TUIP)
      • 11.3.2.3. Robotic Surgeries
      • 11.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
      • 11.3.2.5. Prostatic Urethral Lift
      • 11.3.2.6. Others
    • 11.3.3. Laser Therapy
    • 11.3.4. Others
  • 11.4. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
    • 11.4.1. Hospitals
    • 11.4.2. Ambulatory Surgical Centers
    • 11.4.3. Specialty Clinics
    • 11.4.4. Others
  • 11.5. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
    • 11.5.1. China
    • 11.5.2. India
    • 11.5.3. Japan
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
    • 11.6.1. By Treatment
    • 11.6.2. By End-user
    • 11.6.3. By Country/Sub-region

12. Latin America Benign Prostatic Hyperplasia Treatment Market Analysis

  • 12.1. Latin America Benign Prostatic Hyperplasia Treatment Market Key Findings
  • 12.2. Latin America Benign Prostatic Hyperplasia Treatment Market Overview
  • 12.3. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
    • 12.3.1. Drug Class
      • 12.3.1.1. Alpha-blockers
      • 12.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
      • 12.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 12.3.1.4. Others
    • 12.3.2. Minimally Invasive Surgeries
      • 12.3.2.1. Transurethral Resection of the Prostate (TURP)
      • 12.3.2.2. Transurethral Incision of the Prostate (TUIP)
      • 12.3.2.3. Robotic Surgeries
      • 12.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
      • 12.3.2.5. Prostatic Urethral Lift
      • 12.3.2.6. Others
    • 12.3.3. Laser Therapy
    • 12.3.4. Others
  • 12.4. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
    • 12.4.1. Hospitals
    • 12.4.2. Ambulatory Surgical Centers
    • 12.4.3. Specialty Clinics
    • 12.4.4. Others
  • 12.5. Latin America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
    • 12.6.1. By Treatment
    • 12.6.2. By End-user
    • 12.6.3. By Country/Sub-region

13. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Analysis

  • 13.1. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market
  • 13.2. Benign Prostatic Hyperplasia Treatment Market Overview
  • 13.3. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
    • 13.3.1. Drug Class
      • 13.3.1.1. Alpha-blockers
      • 13.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
      • 13.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 13.3.1.4. Others
    • 13.3.2. Minimally Invasive Surgeries
      • 13.3.2.1. Transurethral Resection of the Prostate (TURP)
      • 13.3.2.2. Transurethral Incision of the Prostate (TUIP)
      • 13.3.2.3. Robotic Surgeries
      • 13.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
      • 13.3.2.5. Prostatic Urethral Lift
      • 13.3.2.6. Others
    • 13.3.3. Laser Therapy
    • 13.3.4. Others
  • 13.4. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
    • 13.4.1. Hospitals
    • 13.4.2. Ambulatory Surgical Centers
    • 13.4.3. Specialty Clinics
    • 13.4.4. Others
  • 13.5. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
    • 13.6.1. By Treatment
    • 13.6.2. By End-user
    • 13.6.3. By Country/Sub-region

14. Competitive Landscape (Pharmaceutical Companies)

  • 14.1. Company Profiles
    • 14.1.1. Abbott
      • 14.1.1.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.1.2. Financials
      • 14.1.1.3. Recent Developments
      • 14.1.1.4. Strategy
    • 14.1.2. Allergan plc
      • 14.1.2.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.2.2. Financials
      • 14.1.2.3. Recent Developments
      • 14.1.2.4. Strategy
    • 14.1.3. Astellas Pharma, Inc.
      • 14.1.3.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.3.2. Financials
      • 14.1.3.3. Recent Developments
      • 14.1.3.4. Strategy
    • 14.1.4. Asahi Kasei Corporation
      • 14.1.4.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.4.2. Financials
      • 14.1.4.3. Recent Developments
      • 14.1.4.4. Strategy
    • 14.1.5. Boehringer Ingelheim GmbH
      • 14.1.5.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.5.2. Financials
      • 14.1.5.3. Recent Developments
      • 14.1.5.4. Strategy
    • 14.1.6. GlaxoSmithKline plc
      • 14.1.6.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.6.2. Financials
      • 14.1.6.3. Recent Developments
      • 14.1.6.4. Strategy
    • 14.1.7. Pfizer, Inc.
      • 14.1.7.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.7.2. Financials
      • 14.1.7.3. Recent Developments
      • 14.1.7.4. Strategy
    • 14.1.8. Sanofi
      • 14.1.8.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.8.2. Financials
      • 14.1.8.3. Recent Developments
      • 14.1.8.4. Strategy
    • 14.1.9. Teva Pharmaceutical Industries Ltd.
      • 14.1.9.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.9.2. Financials
      • 14.1.9.3. Recent Developments
      • 14.1.9.4. Strategy
    • 14.1.10. Merck & Co., Inc.
      • 14.1.10.1. Overview (HQ, Employee Strength, Business Segments)
      • 14.1.10.2. Financials
      • 14.1.10.3. Recent Developments
      • 14.1.10.4. Strategy

15. Competitive Landscape (Medical Devices/Service Provider Organizations)

  • 15.1. Company Profiles
    • 15.1.1. Boston Scientific Corporation
      • 15.1.1.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.1.2. Financials
      • 15.1.1.3. Recent Developments
      • 15.1.1.4. Strategy
    • 15.1.2. Teleflex Incorporated
      • 15.1.2.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.2.2. Financials
      • 15.1.2.3. Recent Developments
      • 15.1.2.4. Strategy
    • 15.1.3. Endo International plc
      • 15.1.3.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.3.2. Financials
      • 15.1.3.3. Recent Developments
      • 15.1.3.4. Strategy
    • 15.1.4. Urologix, LLC
      • 15.1.4.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.4.2. Financials
      • 15.1.4.3. Recent Developments
      • 15.1.4.4. Strategy
    • 15.1.5. LISA Laser
      • 15.1.5.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.5.2. Financials
      • 15.1.5.3. Recent Developments
      • 15.1.5.4. Strategy
    • 15.1.6. Olympus Corporation
      • 15.1.6.1. Overview (HQ, Employee Strength, Business Segments)
      • 15.1.6.2. Financials
      • 15.1.6.3. Recent Developments
      • 15.1.6.4. Strategy
Back to Top
전화 문의
F A Q